PLX 8394

Drug Profile

PLX 8394

Alternative Names: PLX-8394

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator Plexxikon
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hairy cell leukaemia; Malignant melanoma; Solid tumours

Most Recent Events

  • 05 Oct 2016 Phase-I/II development is ongoing in USA
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 Plexxikon initiates a phase I/II trial in Solid tumours (Late-stage disease) in USA (PO) (NCT02428712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top